Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon
Johnson & Johnson Sues US Government Over Rebate Model in Drug Discount Program
Texas Instruments and Other Overlooked Dividend Aristocrat Stocks -- Barrons.com
Disease activity level improvement exceeds 70%. johnson & johnson (JNJ.US) potential heavyweight monoclonal antibody receives breakthrough therapy designation.
Johnson & Johnson (JNJ.US) recently announced that the US FDA has granted breakthrough therapy designation (BTD) to its investigational antibody therapy nipocalimab targeting the neonatal Fc receptor (FcRn), for the treatment of adult patients with moderate to severe Sjogren's syndrome.
J&J Sues HHS Over 340B Hospital Drug-discount Program
J&J Sues U.S. Over Hospital Drug-Discounting Program -- WSJ